Showing 1 - 2 results of 2 for search 'Kei-ji Sugimoto', query time: 0.03s Refine Results
  1. 1
    Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N‐Road study

    Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): Th... by Kaichi Nishiwaki, Kei‐ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Arinobu Tojo, Hisashi Wakita

    Published 2020-06-01
    Get full text
    Article
  2. 2
    Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response

    Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response by Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K. Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara

    Published 2022-10-01
    Get full text
    Article

Search Tools: